Cargando…

Advanced Glycation End Products and Psoriasis

Advanced glycation end products (AGEs) are biologically active compounds formed physiologically throughout a sequence of chemical reactions, to generate highly oxidant-reactive aldehydes that combine covalently to proteins. They accumulate slowly in tissues during ageing but also in metabolic and se...

Descripción completa

Detalles Bibliográficos
Autores principales: Maurelli, Martina, Gisondi, Paolo, Girolomoni, Giampiero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056603/
https://www.ncbi.nlm.nih.gov/pubmed/36992201
http://dx.doi.org/10.3390/vaccines11030617
_version_ 1785016163219013632
author Maurelli, Martina
Gisondi, Paolo
Girolomoni, Giampiero
author_facet Maurelli, Martina
Gisondi, Paolo
Girolomoni, Giampiero
author_sort Maurelli, Martina
collection PubMed
description Advanced glycation end products (AGEs) are biologically active compounds formed physiologically throughout a sequence of chemical reactions, to generate highly oxidant-reactive aldehydes that combine covalently to proteins. They accumulate slowly in tissues during ageing but also in metabolic and selected inflammatory disorders. Accumulation of AGEs occurs more rapidly and intensely in the skin and serum of patients with type 2 diabetes, obesity, cardiovascular diseases, chronic renal insufficiency, and non-alcoholic fatty liver disease and also in the skin of patients with psoriasis. All of the above conditions are intimately associated with psoriasis. Interaction of AGEs with their receptors (RAGEs) stimulates cellular signaling with the formation of reactive oxygen species and activation of nuclear factor kappa light chain enhancer of activated B (NF-kB), which is a key regulator in the expression of inflammatory mediators and the production of oxidative stress. Thus, AGEs may play an interesting pathogenic role in the intersection of inflammatory and metabolic diseases, may represent a biomarker of inflammation and a potential target for novel therapeutic strategies. This is a narrative review with the objective to summarize current evidence on the role of AGEs in psoriasis.
format Online
Article
Text
id pubmed-10056603
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100566032023-03-30 Advanced Glycation End Products and Psoriasis Maurelli, Martina Gisondi, Paolo Girolomoni, Giampiero Vaccines (Basel) Review Advanced glycation end products (AGEs) are biologically active compounds formed physiologically throughout a sequence of chemical reactions, to generate highly oxidant-reactive aldehydes that combine covalently to proteins. They accumulate slowly in tissues during ageing but also in metabolic and selected inflammatory disorders. Accumulation of AGEs occurs more rapidly and intensely in the skin and serum of patients with type 2 diabetes, obesity, cardiovascular diseases, chronic renal insufficiency, and non-alcoholic fatty liver disease and also in the skin of patients with psoriasis. All of the above conditions are intimately associated with psoriasis. Interaction of AGEs with their receptors (RAGEs) stimulates cellular signaling with the formation of reactive oxygen species and activation of nuclear factor kappa light chain enhancer of activated B (NF-kB), which is a key regulator in the expression of inflammatory mediators and the production of oxidative stress. Thus, AGEs may play an interesting pathogenic role in the intersection of inflammatory and metabolic diseases, may represent a biomarker of inflammation and a potential target for novel therapeutic strategies. This is a narrative review with the objective to summarize current evidence on the role of AGEs in psoriasis. MDPI 2023-03-08 /pmc/articles/PMC10056603/ /pubmed/36992201 http://dx.doi.org/10.3390/vaccines11030617 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Maurelli, Martina
Gisondi, Paolo
Girolomoni, Giampiero
Advanced Glycation End Products and Psoriasis
title Advanced Glycation End Products and Psoriasis
title_full Advanced Glycation End Products and Psoriasis
title_fullStr Advanced Glycation End Products and Psoriasis
title_full_unstemmed Advanced Glycation End Products and Psoriasis
title_short Advanced Glycation End Products and Psoriasis
title_sort advanced glycation end products and psoriasis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056603/
https://www.ncbi.nlm.nih.gov/pubmed/36992201
http://dx.doi.org/10.3390/vaccines11030617
work_keys_str_mv AT maurellimartina advancedglycationendproductsandpsoriasis
AT gisondipaolo advancedglycationendproductsandpsoriasis
AT girolomonigiampiero advancedglycationendproductsandpsoriasis